Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Operations

v3.20.4
Consolidated Statement of Operations - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Total revenue $ 18,845,000 $ 22,270,000
Operating expenses:    
Research and development 92,965,000 50,519,000
General and administrative 26,722,000 20,077,000
Loss on impairment of in-process research and development 0 22,123,000
Total operating expenses 119,687,000 92,719,000
Loss from operations 100,842,000 70,449,000
Interest and other income, net 1,028,000 2,323,000
Interest and other expense, net (1,705,000) (1,298,000)
Loss on extinguishment of debt (1,237,000) 0
Loss on disposal of assets (2,155,000) 0
Change in fair value of warrant liabilities 0 3,000
Loss before provision for income taxes 104,911,000 69,421,000
Provision for income taxes 5,000.00 0.00
Net loss 104,916,000 69,421,000
Net loss attributable to common shareholders $ 104,916,000 $ 69,421,000
Net loss per share attributable to common shareholders:    
Basic and diluted $ 2.20 $ 1.86
Weighted average number of shares used in net loss per share calculations:    
Basic and diluted 47,603,261 37,770,378
Research And Development Revenue | Other    
Total revenue $ 9,068,000 $ 0
Research And Development Revenue | Related Party    
Total revenue 6,567,000 19,499,000
Grant    
Total revenue $ 3,210,000 $ 2,771,000